Actualités et Activités de Jasper Therapeutics
Dirigeants
Voir l'organigramme avec ses 19 principaux dirigeants
Biographies les plus recherchées chez Jasper Therapeutics
- Jeet Mahal, President and Chief Executive Officer and Director
- Judith Shizuru, Director
- Thomas Wiggans, Executive Chairman of the Board
Changements de dirigeants chez Jasper Therapeutics
- Chris Nolet, Director, a quitté l'entreprise (publié le 22 mai 2026).
- Ronald Martell, Chief Executive Officer and Director, a quitté l'entreprise (publié le 8 janvier 2026).
- Jeet Mahal qui était Chief Operating Officer, est promu President and Chief Executive Officer and Director (publié le 8 janvier 2026).
Créer une alerte
pour suivre les mouvements de dirigeants chez Jasper Therapeutics.
Biotechnologie
Jasper Therapeutics a 2 405 concurrents dont Eurofins (Luxembourg), Lonza (Suisse) et BioNTech (Allemagne).
Actualités en fusion/acquisition en Biotechnologie.
- IMU Biosciences vient d'annoncer une levée de fonds de 53 millions de dollars. (publié le 3 juin 2026).
- NewLimit vient d'annoncer une levée de fonds de 435 millions de dollars. (publié le 3 juin 2026).
- Rallybio and Avenzo Therapeutics have announced they will merge (publié le 1 juin 2026)..
Contacts en Biotechnologie
Actualités
Derniers communiqués de presse par Jasper Therapeutics
- News Releases | Jasper Therapeutics, Inc
- News Releases | Jasper Therapeutics, Inc
- Jasper Therapeutics and Aruvant Announce Research Collaboration to Study JSP191, an Antibody-Based Conditioning Agent, with ARU-1801, a Novel Gene Therapy for the Treatment of Sickle Cell Disease
- Jasper Therapeutics Announces Orphan Drug and Rare Pediatric Disease Designations for JSP191 for Conditioning Treatment Prior to Stem Cell Transplant | Business Wire
- Jasper Therapeutics to Host Webcast to Review Updated 90-day Data from Phase 1 Clinical Trial of JSP191 That is Being Presented at 2021 ASCO Virtual Annual Meeting | Business Wire
- Jasper Therapeutics Announces New Clinical Trial with the National Institute of Allergy and Infectious Diseases to Evaluate JSP191 in Chronic Granulomatous Disease | Business Wire
- Jasper Therapeutics Announces Updated 90-day Data from Phase 1 Clinical Trial of JSP191 as Targeted Stem Cell Conditioning Agent in Older Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation | Bus
- Jasper Therapeutics and Amplitude Healthcare Acquisition Corporation Announce Merger to Create a Publicly Listed Leading Biotechnology Company in Hematopoietic Stem Cell Transplantation | Business Wire
- Jasper Therapeutics Announces Launch of New Clinical Trial with National Heart, Lung, and Blood Institute to Evaluate JSP191 in Sickle Cell Disease | Business Wire
- Jasper Therapeutics Announces Positive Data from Phase 1 Clinical Trial of JSP191 as Targeted Stem Cell Conditioning Agent in Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation | Business Wire
- Voir plus de communiqués de presse Close
Réseaux sociaux à propos de Jasper Therapeutics
- Jasper Therapeutics sur Wikipédia, Google News & Yahoo Finance en 1-click
- Jasper Therapeutics sur LinkedIn, X (Twitter) & YouTube en 1-click
